



# EUROPEAN MALARIA VACCINE INITIATIVE

## Perspectives for the future

Egeruan Babatunde Imoukhuede

Dir, Clinical & Regulatory Affairs

[babatunde.imoukhuede@emvi.org](mailto:babatunde.imoukhuede@emvi.org)

*EDCTP Forum, Arusha. 14/10/2009*



# OUTLINE

- Introduction – EMVI Mission, funding
- EMVI Partners
- Transformation of EMVI to EVI - EEIG
- EDCTP Consortia
- Formation of EVI - EEIG



## EMVI mission


- To contribute to the global efforts to control malaria by:
  - providing a mechanism *for accelerated development of malaria vaccines in Europe and Developing Countries*
  - promoting affordability and accessibility of malaria vaccines in Developing Countries




# EMVI Funding structure

- 2 types of funding:
  - Core funding from EU Member States
  - EC projects
- EMVI is a partnership of 4 European Member States and receives **public** funds only, mostly from Development Aid agencies
  - Sweden (SIDA/SAREC)
  - Ireland (Irish Aid)
  - Denmark (DANIDA)
  - The Netherlands (DGIS)

# EMVI - Vaccine Development /Partnership



# EMVI - Partnership



# Why the European Vaccine Initiative?

1/3

- Fragmentation of Public-funded Vaccine R&D in Europe
  - Lack of common strategy and coordination in the public sector.
  - EU Member States Public sector provides limited countervailing power.
  - Too limited collaboration/cooperation with Private sector

# Why the European Vaccine Initiative?

2/3

- Creation of European Vaccine Initiative
  - Federation of institutions/organisations involved in EU vaccine R&D
  - Network that provides knowledge based, development expertise and facilities that enable follow-up on an European vaccine agenda .
  - Network with other stakeholders
- Synergy with Private sector
- Global collaboration, coordination and harmonisation activities

# Why the European Vaccine Initiative?

3/3

- EMVI is the coordinator of 5 EU projects
  - Integrated Project – EMVDA
  - Specific Supported Action – EURHAVAC
  - Coordination action: INYVAX/  
OPTIMALVAC
  - Infrastructure action TRANSVAC – 2009-2013  
(Malaria, Tb, HIV)
- EMVI is partner of 2 EU Coordination Action projects:
  - PHARVAT
  - **IDEA** - Impact of PRD co-infections on vaccine immune response
    - Coordinator : Swiss Vaccine Research Institute GP Pantaleo
    - EMVI WP leader for **TB, HIV and Malaria vaccine clinical trials**
- EMVI is partner in the EDCTP funded GMZ2 Consortium and coordinator of the recently approved Vectored Vaccines Consortium



# EDCTP CONSORTIA

- **GMZ2 Consortium (approved 2008)**


- Malaria Vaccines Integrated project (Clinical Trials/Capacity Building/Networking)
- 5 yr project (2008-2013), Total budget 9.5 million Euros
- 7 partners (AMANET, UKT Tubingen, CNRFP, MRC The Gambia, Makerere University, MRU Lambarene, **EMVI**)
- Dr Ramadhani Noor (AMANET) as coordinator

- **Vectored Vaccines Consortium (approved 2009)**

- Malaria Vaccines Integrated project (Clinical Trials/Capacity Building/Networking)
- 4 yr project (2009-2014), Grant agreement negotiations on-going
- 8 partners (UOXF, Okairos, VSCR, CNRFP, MRC The Gambia, UCAD, KEMRI-Kilifi, **EMVI**)
- Dr Babatunde Imoukhuede (EMVI) as coordinator

# European Vaccine Initiative


- European Economic Interest Group
- EVI legal seat is in Heidelberg (Germany)
- Existing contracts are currently being transferred from EMVI to EVI-EEIG





# CONCLUSION

- Emphatically state that EVI will continue to adhere to its core mission of accelerating the development of vaccines for poverty-related diseases especially malaria
- Additionally, EVI will increase its activities in the global coordination and harmonisation of activities related to the poverty related disease



**TEAM WORK DIVIDES THE EFFORT  
and  
MULTIPLIES THE EFFECT**



To God be the Glory

**Asante Sana'**

[babatunde.imoukhuede@emvi.org](mailto:babatunde.imoukhuede@emvi.org)